Robert L. Kirkman, MD, President and CEO, Oncothyreon, discusses the evaluation of ONT-380, an oral HER2-specific inhibitor, for the treatment of patents with HER2-positive metastatic breast cancer.

Two phase I trials are underway, looking at ONT-380 in combination with T-DM1 and in combination with capecitabine and trastuzumab.

A phase I trial with ONT-380 has been evaluated in this population of patients as well as a few patients with HER2-positive gastric cancer, Kirkman says. This analysis showed that ONT-380 is well tolerated and EGFR-related side effects were not observed. In a highly-pretreated population of patients with HER2-positive breast cancer, ONT-380 elicited a clinical benefit rate of 27%.

Videos

Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

Robert L. Kirkman, MD, the president, chief executive officer of Oncothyreon in Seattle, WA, discusses results from a phase I/II study looking at the combination of docetaxel and PX-866, a small molecule PI3-kinase inhibitor, for patients with multiple tumor types, including non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN).

The trial enrolled 43 patients with multiple advanced solid tumors and investigated the role of possible biomarkers, tumor shrinkage, disease control, and the time on the study. In total, the disease control rate for patients receiving the combination of PX-866 and docetaxel was 75%. Additionally, the trial found that patients with a mutation in the 

 gene demonstrated a longer time on the study.

These results have caused researchers to investigate the combination more specifically in patients with NSCLC and SCCHN, Kirkman notes. These trials have already begun enrolling patients.

Dr. Robert Kirkman, the CEO of Oncothyreon, on the Combination of PX-866 and Docetaxel

Robert L. Kirkman, MD

Articles

Dr. Kirkman on the Novel HER2-Specific Inhibitor ONT-380 for Breast Cancer

Dr. Kirkman on the Combination of PX-866 and Docetaxel